A5009263584- Multiple Myeloma Research and Treatments
- Cancer Treatment and Pharmacology
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Erythropoietin and Anemia Treatment
- Hematopoietic Stem Cell Transplantation
- Lymphoma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Peptidase Inhibition and Analysis
- Myasthenia Gravis and Thymoma
- Acute Myeloid Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Peripheral Neuropathies and Disorders
- Pancreatitis Pathology and Treatment
- Public Health and Environmental Issues
- Acute Lymphoblastic Leukemia research
- Testicular diseases and treatments
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Eosinophilic Disorders and Syndromes
- Bipolar Disorder and Treatment
- Cardiovascular Effects of Exercise
- Abdominal vascular conditions and treatments
- HIV/AIDS drug development and treatment
- Abdominal Trauma and Injuries
- Hereditary Neurological Disorders
Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno
2007-2024
Helios Salud
2023
Hospital Universitario Austral
2022
GlaxoSmithKline (United States)
2019
Hospital Alemán
2007
Waldenstrom Macroglobulinemia (WM) is a rare lymphoma with distinct clinical features, and data from Latin American patients are lacking. Therefore, we aim to investigate the clinical, therapy, outcome patterns of WM in America.We retrospectively analyzed diagnosed between 1991 2019 24 centers seven countries. The study outcomes were overall survival (OS) progression-free (PFS).We identified 159 cases (median age 67 years, male 62%). Most (95%) symptomatic at diagnosis. International...
The aim of this study was to describe clinical and survival characteristics transplant-eligible multiple myeloma (MM) patients in Latin America (LA), with a special focus on differences between public private healthcare facilities. We included 1293 diagnosed 2010 2018. A great disparity outcomes both groups observed. Late diagnosis low access adequate frontline therapy ASCT institutions probably explain these differences. Patients treated novel drug induction protocols, followed by...
Primary plasma cell leukemia (pPCL) is an infrequent and aggressive disorder. The prognosis still very poor, the optimal treatment remains to be established. A retrospective, multicentric, international observational study was performed. Patients from 9 countries of Latin America (LATAM) with a diagnosis pPCL between 2012 2020 were included. 72 patients Treatment based on thalidomide in 15%, proteasome inhibitors (PI)-based triplets 38% chemotherapy plus IMIDs and/or PI 29%. mortality rate...
PURPOSE Multiple myeloma (MM) is a highly heterogeneous, incurable disease most frequently diagnosed in the elderly. Therefore, data on clinical characteristics and outcomes very young population are scarce. PATIENTS AND METHODS We analyzed characteristics, response to treatment, survival 103 patients with newly MM age 40 years or younger compared 256 41-50 957 51 older. RESULTS There were no statistical differences sex, isotype, International Scoring System, renal involvement,...
Data about treatment outcomes and toxicity in Latin America are scarce. There differences with central countries based on access to healthcare system socioeconomic status. Argentinean Society of Hematology recommends bortezomib-based triplets for induction transplant eligible newly diagnosed multiple myeloma patients. Most common options CyBorD (cyclophosphamide, bortezomib dexamethasone) VTD (bortezomib, thalidomide dexamethasone). Main goal our retrospective, multicentric study was compare...
There have been several efforts to predict mortality after autologous stem cell transplantation (ASCT), such as the hematopoietic transplant-comorbidity index (HCT-CI), described for allogeneic and validated ASCT, but there is no composite score in setting of ASCT combining comorbidities with other clinical characteristics. Our aim describe a comprehensive factors analyze impact this on nonrelapse (NRM), overall survival (OS), early morbidity endpoints (mechanical ventilation, shock or...
We compared the efficacy of lenalidomide-dexamethasone (Rd) based treatments for relapsed/refractory multiple myeloma patients (pts), in a real-world setting. In addition, we evaluated adverse events (AE), progression-free survival (PFS) and overall (OS).In our retrospective, multicentric study, 156 pts with RRMM were included. 74/156 (47%) refractory to bortezomib (V) 43/156 (27%) lenalidomide (R), 24/156 (15%) double refractory. Eighty-six (55%) received Rd carfilzomib (KRd), 30 (19%)...
508 Background: Germ cell tumors (GCTs) are the most common type of cancer in adolescent and young adult males. Most them curable with multimodal treatment: platinum-based chemotherapy (CT) + surgery. Patients who fail first-line treatment usually receive salvage CT response rates between 30 50%. High-dose autologous hematopoietic stem transplantation (HDCT) is an effective this context. Methods: We conducted a multicenter retrospective analysis patients ≥ 15 years old relapsed/refractory...
Introduction: POEMS syndrome is a rare paraneoplastic caused by an underlying plasma cell disorder. The acronym refers to the following features: polyradiculoneuropathy, organomegaly, endocrinopathy, monoclonal paraproteinemia, and skin changes. Methods: study was conducted at 24 hematological centers across 8 Latin-American countries. included total of 46 patients {median age 52 years (interquartile range [IQR]: 42–61.5), 30 males 16 females} fulfilling criteria diagnosed over period 12...
High-dose chemotherapy followed by ASCT is the standard treatment for pts with relapsed HL and non-HL also part of first line therapy in mantle cell (MCL) or peripheral T-cell lymphoma. Various conditioning regimens have been used none demonstrated superiority to another. Since 1990's association carmustine (BCNU), etoposide cyclophosphamide (CBV) was care Argentina. As BCNU unavailable since 2013 we had design an alternative regimen replacing bendamustine CBV. Bendamustine associates...
Background: Multiple myeloma (MM) is a clonal B cell malignancy characterized by the presence of multiple structural and numerical genetic alterations, including gains, losses rearrangements different chromosomal regions. Among them, partial deletion long arm chromosome 6 [del(6q)] common recurrent abnormality in MM, observed 20-35% patients. Despite this, there no data about this alteration from MM patients Latin America (LA). Aims: To evaluate frequency, distribution clinical...